References
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s diseases. N Engl J Med. 1999;340:1398–405.
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85.
Colombel JF, Loftus Jr EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease; the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.
Naranjo A, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.
Agarwal PK, Gallaghar M, Murphy E, Virdi M. Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker. Indian J Ophthalmol. 2007;55:230–2.
Anonymous. Adalimumab/etanercept/infliximab: endophthalmitis leading to vision loss: 3 case reports. Reactions Weekly July, 12, 2008.
Schiedler V, Scott IU, Flynnir HW Jr, Davis JL, Benz MS, Miller D. Culture-proven endogenous endophlhalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol. 2004;137:725–31.
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kochhar, R., Gupta, V., Dutta, U. et al. Infliximab induced endophthalmitis in a patient of fistulizing Crohn’s disease. Indian J Gastroenterol 30, 241–242 (2011). https://doi.org/10.1007/s12664-011-0130-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12664-011-0130-8